Genpact Limited Files Registration Statement with SEC for Initial Public Offering
New York, NY (May 11, 2007) – Genpact Limited, which manages business processes for companies around the world, today announced it has filed a registration statement with the U.S. Securities and Exchange Commission for a proposed initial public offering of its common shares. Genpact will apply to have its common shares listed on the NYSE under the symbol “G”.
The joint bookrunning managers are Morgan Stanley, Citi and JPMorgan.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
A copy of the prospectus relating to these securities may be obtained, when available, from the Prospectus Department of Morgan Stanley & Co. Incorporated, 180 Varick Street, 2nd Floor, New York, NY 10024.
About Genpact
Genpact manages business processes for companies around the world. Genpact combines its process expertise, information technology expertise and its analytical capabilities together with operational insight derived from its experience in diverse industries to provide a wide range of services using its global delivery platform. Genpact's goal is to help its clients improve the ways in which they do business by continuously improving their business processes, including through the application of Six Sigma and Lean principles and by leveraging technology. Genpact has more than 28,000 employees across 25 delivery centers located in India, China, Hungary, Mexico, the Philippines, the Netherlands, Romania, Spain and the United States.
FOR MORE INFORMATION, CONTACT:
David Jensen
david.jensen@genpact.com
203 325 8676 / 203 252-8562
